At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Ranolazine 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Ranolazine in LQT3 Patients
In Brief
A Phase 2 clinical trial evaluating Placebo and Ranolazine for Long QT Syndrome. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether late sodium channel blockade might be effective in shortening the QTc interval in various LQT3 mutations and be considered as a safe therapeutic option for LQT3 patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLong QT Syndrome
CountriesUnited States
CollaboratorsGilead Sciences
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartSep 2012
Primary CompletionJul 2018
TodayJul 2026
First PostedJul 24, 2012
Enrollment StartSep 1, 2012
Primary CompletionJul 20, 2018
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.9 years ago
Interventions
Placebodrug
Matching Placebo will be given for first month.
Ranolazinedrug
Patients will receive ranolazine 1000mg bid for subsequent 5 months.